Westlake Village, CA January 30, 2025 – FlemingMartin is pleased to announce that Genelux (NASDAQ: GNLX), a leading innovator in the field of cancer immunotherapy, has hired Matt Pulisic as their Chief Financial Officer.
Most recently, Matt served as Vice President of Finance at Arrowhead Pharmaceuticals, Inc., a publicly traded RNAi technology company, from August 2020 to January 2025. Prior to that, Mr. Pulisic served as Head of Finance for Global Product Development, R&D, Global Marketing & Sourcing at HARMAN International, a standalone subsidiary of Samsung Electronics Co. Ltd., from August 2019 to August 2020. He began his career at Amgen, Inc., a publicly traded commercial biotechnology company, in April 2006 as a Research Associate and transitioned into finance where he held multiple positions of increasing responsibility, including Commercial Finance, Corporate Finance, Treasury, Head of Capital Finance & Finance Director for Amgen Worldwide, spanning from 2007 to 2019. Matt earned his MBA in Finance from California Lutheran University, School of Business and holds a BSc in Biochemistry and Molecular Biology from the University of California, Santa Cruz.
Matt is deeply committed to advancing healthcare and improving patient outcomes. He has a proven track record of success, having led diverse teams in financial management across the U.S., Europe, and Asia. Matt’s broad experience spans key financial disciplines including capital investments, treasury, tax, and operations, making him a well-rounded leader ready to support Genelux’s growth and innovation in the biotech industry.